Medical Editor: John P. Cunha, DO, FACOEP
Luxiq (betamethasone valerate) is a topical corticosteroid used to treat skin conditions of the scalp such as psoriasis or seborrhea (dandruff). Common side effects of Luxiq include application site reactions (mild burning, stinging, redness, peeling, or itching), thinning of your skin, skin discoloration, blistering skin, stretch marks, unwanted hair growth, or "hair bumps" (folliculitis).
Luxiq is supplied in 150 gram, 100 gram, and 50 gram doses. Avoid getting this medication in your eyes, mouth, and nose, or on your lips. If it does get into any of these areas, wash with water. Luxiq may interact with other corticosteroids. Tell your doctor all medications you use. If you are pregnant, talk with your doctor about risks and benefits. Consult your doctor before breastfeeding.
Our Luxiq (betamethasone valerate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these signs that you may be absorbing betamethasone topical through your skin or gums:
- blurred vision, or seeing halos around lights;
- uneven heartbeats;
- mood changes;
- sleep problems (insomnia);
- weight gain, puffiness in your face; or
- feeling tired.
Less serious side effects may include:
- skin redness, burning, itching, or peeling;
- thinning of your skin; or
- blistering skin; or
- stretch marks.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Luxiq (Betamethasone Valerate Foam)
The most frequent adverse event was burning/itching/stinging at the applica-tion site; the incidence and severity of this event were as follows:
|incidence and severity of burning/itching/stinging|
|Product||Total incidence||Maximum severity|
|Luxiq Foam n=63||34 (54%)||28 (44%)||5 (8%)||1 (2%)|
|Betamethasone valerate lotion n=63||33 (52%)||26 (41%)||6 (10%)||1 (2%)|
|Placebo Foam n=32||24 (75%)||13 (41%)||7 (22%)||4 (12%)|
|Placebo Lotion n=30||20 (67%)||12 (40%)||5 (17%)||3 (10%)|
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximately decreas-ing order of occurrence: irritation; dryness; folliculitis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; secondary infection; skin atrophy; striae; and miliaria.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Read the entire FDA prescribing information for Luxiq (Betamethasone Valerate Foam)
© Luxiq Patient Information is supplied by Cerner Multum, Inc. and Luxiq Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.